X

Trial Profile

Phase II study on ET-743 in BRCA1 and BRCA2 mutation carrier and BRCAness phenotype advanced ovarian cancer patients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Oct 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trabectedin (Primary)
Indications Ovarian cancer
Focus Pharmacogenomic; Therapeutic Use
Acronyms MITO 15
Sponsors PharmaMar

Most Recent Events

01 Oct 2016 Status changed from active, no longer recruiting to completed.
17 Dec 2015 Results published in the Annals of Oncology
15 May 2014 According to the PharmaMar media release, results of this trail presented at 2014 Annual Meeting of American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com